Pain Reduction Improves Adherence, Quality of Life, and Work Capacity in Rheumatoid Arthritis Patients Receiving Baricitinib: Czech ATTRA Registry Analysis
Treatment with baricitinib provided sustained pain reduction and decreased disease activity in patients with RA. Findings highlight the need for pain-focused treatment goals and suggest earlier intervention may enhance persistence and QoL. Work limitations persisted, highlighting the need for flexible employment policies.
Authors
- Jana Šilarová
- Jakub Závada (ORCID: https://orcid.org/0000-0002-9802-6545)
- Ladislav Šenolt (ORCID: https://orcid.org/0000-0001-5500-7312)
- E. Haladyj
- I Vachova
- Karel Pavelka
- Lenka Klementová
Institutions
- Eli Lilly (United States) (US)
- Institute of Rheumatology (CZ)
Publication Details
- Journal
- Rheumatology and Therapy
- Published
- 2026-03-09
- DOI
- https://doi.org/10.1007/s40744-026-00837-2
- Primary Topic
- Rheumatoid Arthritis Research and Therapies
- Type
- article
- Field-Weighted Citation Impact
- 0.00